Sun Pharma $13bn Organon bid drives Organon up 30%

What triggered the sudden move in Organon stock

Organon & Co. (NYSE: OGN) rallied sharply after reports said Sun Pharmaceutical Industries has submitted a binding bid of about US$13 billion to acquire the US-based drugmaker. The reported offer is higher than earlier media references of a US$12 billion proposal, signalling that negotiations have moved into a more competitive phase. Pre-market trading in Organon saw the stock surge 29.65% and touch a 20-day high. In regular morning trading, the stock was reported up 26%, or US$1.83, to US$1.74.

The developments matter for investors in both stocks because the deal size is unusually large for an outbound acquisition by an Indian pharmaceutical company. The newsflow also added a clear M&A catalyst to a stock that has been discussed as having a leveraged balance sheet and muted growth expectations. Attention has shifted to what potential buyers may see in Organon’s portfolio, cash generation, and carve-out value.

Sun Pharma’s reported bid: from US$12bn to US$13bn

Multiple reports referenced Sun Pharma evaluating Organon with a transaction size pegged around US$12 billion, before later reports said a binding bid of nearly US$13 billion was submitted. One account described an earlier non-binding offer of about US$10 billion, followed by a step-up to around US$12 billion as discussions progressed. The latest update in the supplied information states the binding bid was raised to US$13 billion, from the prior US$12 billion.

People familiar with the matter were cited as saying Sun Pharma completed more than three months of due diligence and was working on financing. Global banks named in the reports include JPMorgan and MUFG, with another report stating the offer is fully financed by JPMorgan, MUFG and Citi to the tune of US$12 billion. Separate reporting also mentioned MUFG and Standard Chartered Bank as financing partners in the broader process.

Competitive process: EQT and Grünenthal in the mix

The acquisition process is described as competitive, with Swedish private equity firm EQT and German pharmaceutical company Grünenthal also reported to be in contention. Grünenthal was described as a specialist in pain management. The presence of multiple bidders helps explain both the jump in Organon’s share price and the reported increase in Sun Pharma’s offer size.

Organon is highlighted as having a strong position in women’s health, with coverage across areas such as breast cancer, contraception, osteoporosis, and menopause. Reports also note Organon operates across women’s health, biosimilars and established brands, and that a successful acquisition could add a global women’s health portfolio and US commercial operations to Sun Pharma.

What Sun Pharma has said to exchanges

Even as the media reports escalated from evaluation to due diligence to a binding offer, Sun Pharma’s exchange communication dated April 10, 2026 pushed back on acquisition chatter. The company described the reports as “rumours” and “speculative in nature,” and said there was no material information requiring disclosure under listing regulations, including Regulation 30. The clarification was issued by Anoop Deshpande, Company Secretary and Compliance Officer, in response to queries from BSE and NSE.

That formal stance is important for investors assessing deal certainty because it indicates Sun Pharma has not publicly confirmed a definitive agreement. At the same time, continued reporting around financing talks and a binding offer kept both Sun Pharma and Organon in focus.

Key numbers investors are watching

The supplied information includes several valuation and balance sheet datapoints that are central to market debate around price and execution risk. ICICI Direct estimates cited in the text say that at a reported deal value of US$12 billion, the transaction would value Organon at roughly 2 times CY26 expected sales and about 6 times EBITDA. Organon ended 2025 with US$1.64 billion in debt and guided for 2026 revenue of US$1.1-6.3 billion, versus US$1.4 billion reported for 2025.

Sun Pharma’s financing plan was described as predominantly aimed at taking on Organon’s debt. The company was also reported to have about US$1.2 billion of net cash on its balance sheet that it may deploy to buy the equity of the target.

Market reaction: Organon up, Sun Pharma down

Markets reacted in opposite directions to the possibility of a large all-cash acquisition. Organon shares surged on takeover expectations, including a reported 29% rally following the April 10 report that Sun was preparing to make a final offer. On the other side, Sun Pharma shares fell over 3% on Friday after reports of a potential acquisition surfaced, with analysts raising concerns around valuation and execution risks linked to the deal.

The stock decline was reported as 3.61% to a low of Rs 1,619.05 on the BSE, taking its decline to about 5.4% so far in 2026. In another price reference included in the supplied text, Sun Pharma traded at Rs 1,657.90 on NSE at 12:00 pm on April 13, 2026, up 0.18% (Rs 3.00), after moving between Rs 1,640.10 and Rs 1,668.70 intraday.

Analyst and retail sentiment: BNP Paribas vs Stocktwits

BNP Paribas maintained an Outperform rating on Organon with a US$12 price target after the Economic Times reported Sun Pharma was set to make a US$12 billion offer. BNP said that assuming an enterprise value of US$12 billion, the potential offer could represent fair value of about US$15 per share, or 115% upside from the prior close, and that a potential deal with Sun Pharma could be positive.

Retail sentiment highlighted in the supplied information was more cautious. Despite the strong price action in Organon, Stocktwits retail sentiment was described as bearish, indicating investors were still weighing the probability of a transaction closing and the terms that could emerge from a competitive process.

Snapshot table: reported deal and market datapoints

Why the deal is strategically significant, based on what is known

The reporting frames the proposed acquisition as part of Sun Pharma’s push to evolve from an Indian generics leader into a global branded and innovation-driven drugmaker. Organon’s women’s health franchise, along with biosimilars and established brands, is positioned as an asset that could broaden Sun’s global portfolio and add US front-end commercial operations.

At the same time, Organon’s inherited leverage is a key consideration. Reports say buyers would have to refinance the debt Organon inherited from MSD, and the structure described involves financing that is largely centred on assuming that debt, alongside cash potentially used to purchase equity.

Conclusion

Organon’s sharp rally reflects markets repricing takeover probability after reports of a binding US$13 billion bid from Sun Pharma, alongside competition from EQT and Grünenthal. Sun Pharma, however, has previously called the acquisition headlines speculative in its April 10, 2026 exchange communication. Investors are likely to watch for any further exchange updates or confirmation of definitive agreements as the situation develops, given the scale of the proposed all-cash transaction.